
Sangamo Therapeutics ( ($SGMOQ) ) has issued an update. On June 23, 2026, Sangamo Therapeutics filed for Chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SGMOQ | Sangamo Therapeutics | 0.11 | -0.28 | -71.94% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.11 | -71.94% |

Sangamo Therapeutics ( ($SGMOQ) ) has issued an update. On June 23, 2026, Sangamo Therapeutics filed for Chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware,

An announcement from Sangamo Therapeutics ( ($SGMOQ) ) is now available. On June 23, 2026, Sangamo Therapeutics filed for Chapter 11 protection in the U.S. Bankruptcy Court for the District

Sangamo Therapeutics ( ($SGMOQ) ) has issued an announcement. On June 23, 2026, Sangamo Therapeutics, Inc. filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the

Sangamo Therapeutics ( ($SGMOQ) ) has issued an announcement. On September 4, 2026, Sangamo Therapeutics completed the court-approved sale of substantially all of its key technology platforms and related intellectual

Sangamo Therapeutics ( ($SGMOQ) ) has provided an announcement. On June 23, 2026, Sangamo Therapeutics filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of

Sangamo Therapeutics ( ($SGMOQ) ) has released a notification of late filing. Sangamo Therapeutics, Inc. has filed a Form 12b-25 to notify investors that it will not file its Form

Sangamo Therapeutics ( ($SGMOQ) ) has issued an update. On August 13, 2026, Sangamo Therapeutics, which filed for Chapter 11 protection on June 23, 2026, announced that it had completed

Sangamo Therapeutics ( ($SGMOQ) ) has shared an announcement. As of June 23, 2026, Sangamo Therapeutics filed for voluntary Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the

Sangamo Biosciences (SGMO) is scheduled to report 2nd quarter earnings on 08/11/2026. Regarding Q2 estimates, Wall Street analysts expect Sangamo Biosciences to post earnings of -$0.07 per share. Revenue expectations

Sangamo Therapeutics ( ($SGMOQ) ) just unveiled an announcement. Sangamo Therapeutics, Inc. filed for Chapter 11 bankruptcy protection on June 23, 2026, in the U.S. Bankruptcy Court for the District
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Reiterated | May 14, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 24, 2027TBA | $45.57M | ― | ― | 0.09 | -0.20 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.